User login
WAIKOLOA, HAWAII – What’s going to be the biggest development in the field of psoriasis in 2016?
Hint: Look for a repeat of 2015.
The first of the interleukin-17 antagonists, secukinumab, was the biggest development of 2015, explained Dr. Craig L. Leonardi, associate clinical professor of dermatology at Saint Louis University, St. Louis. “It’s always good when we get another mechanism of action.”
2016 should see the debut of another IL-17 antagonist, ixekizumab, which “seems to be more efficacious than secukinumab,” Dr. Leonardi said in an interview at the Hawaii Dermatology Seminar provided by Global Academy for Medical Education/Skin Disease Education Foundation.
SDEF and this news organization are owned by the same parent company.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
WAIKOLOA, HAWAII – What’s going to be the biggest development in the field of psoriasis in 2016?
Hint: Look for a repeat of 2015.
The first of the interleukin-17 antagonists, secukinumab, was the biggest development of 2015, explained Dr. Craig L. Leonardi, associate clinical professor of dermatology at Saint Louis University, St. Louis. “It’s always good when we get another mechanism of action.”
2016 should see the debut of another IL-17 antagonist, ixekizumab, which “seems to be more efficacious than secukinumab,” Dr. Leonardi said in an interview at the Hawaii Dermatology Seminar provided by Global Academy for Medical Education/Skin Disease Education Foundation.
SDEF and this news organization are owned by the same parent company.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
WAIKOLOA, HAWAII – What’s going to be the biggest development in the field of psoriasis in 2016?
Hint: Look for a repeat of 2015.
The first of the interleukin-17 antagonists, secukinumab, was the biggest development of 2015, explained Dr. Craig L. Leonardi, associate clinical professor of dermatology at Saint Louis University, St. Louis. “It’s always good when we get another mechanism of action.”
2016 should see the debut of another IL-17 antagonist, ixekizumab, which “seems to be more efficacious than secukinumab,” Dr. Leonardi said in an interview at the Hawaii Dermatology Seminar provided by Global Academy for Medical Education/Skin Disease Education Foundation.
SDEF and this news organization are owned by the same parent company.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
AT SDEF HAWAII DERMATOLOGY SEMINAR
